Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis
February 18, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive...
Bellerophon Announces 1-for-15 Reverse Stock Split
February 07, 2020 12:00 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the filing...
Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
December 17, 2019 07:00 ET
|
Bellerophon Therapeutics, Inc.
Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity Bellerophon Intends to Initiate Pivotal Phase 3 in First Quarter of 2020 Company Enters Into $10M...
Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
November 12, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive...
Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019
November 07, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, is presenting data from...
Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results
November 06, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business...
Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting
October 23, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
Results Presented in Late-Breaking Abstract as an Oral PresentationPresentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) --...
Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting
October 14, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
Results to be Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J., Oct. 14, 2019 (GLOBE...
Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis
September 16, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today the U.S....
Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 04, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian...